PHILADELPHIA, Sept. 5,
2023 /PRNewswire/ -- Carisma Therapeutics Inc.
(Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage
biopharmaceutical company focused on discovering and developing
innovative immunotherapies, today announced that it will present at
several upcoming investor conferences, including:
H.C. Wainwright 25th Annual Global Investment
Conference
- Steven Kelly, President and
Chief Executive Officer, will give a corporate presentation.
- Monday, September 11 at
11:00 am ET
- New York City
Baird Global Healthcare Conference 2023
- Steven Kelly, President and
Chief Executive Officer, will participate in a fireside chat.
- Wednesday, September 13 at
11:25 am ET
- New York City
Jefferies Cell & Genetic Medicine Summit
- Steven Kelly, President and
Chief Executive Officer, will participate in a fireside chat.
- Wednesday, September 27 at
11:00 am ET
- New York City
Chardan's 7th Annual Genetic Medicines
Conference
- Steven Kelly, President and
Chief Executive Officer, will participate in a fireside chat.
- Monday, October 2 at 1:00 pm ET
- New York City
The Cell & Gene Meeting on the Mesa
- Steven Kelly, President and
Chief Executive Officer, will give a corporate presentation.
- Tuesday, October 10 at
4:30 pm PT
- Carlsbad, CA
Live webcasts will be available on the Company's Investor Events
webpage. A replay of the webcasts will be archived at the Company's
past events section of the Investor Relations webpage for a limited
time following the event.
About Carisma
Carisma is a clinical stage biopharmaceutical company focused on
utilizing our proprietary macrophage and monocyte cell engineering
platform to develop transformative immunotherapies to treat cancer
and other serious diseases. We have created a comprehensive,
differentiated proprietary cell therapy platform focused on
engineered macrophages and monocytes, cells that play a crucial
role in both the innate and adaptive immune response. Carisma is
headquartered in Philadelphia, PA.
For more information, please visit www.carismatx.com.
Cautionary Note on Forward-Looking Statements
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
"forward-looking statements" within the meaning of The Private
Securities Litigation Reform Act of 1995. These statements include,
but are not limited to, statements relating to Carisma's business,
strategy, future operations, cash runway, the advancement of
Carisma's product candidates and product pipeline, and clinical
development of Carisma's product candidates, including expectations
regarding timing of initiation and results of clinical trials,
ability to replicate in later clinical trials positive results
found in preclinical studies and early-stage clinical trials of its
product candidates, and participation by Carisma in future
healthcare industry and investor conferences. The words
"anticipate," "believe," "contemplate," "continue," "could,"
"estimate," "expect," "goals," "intend," "may," "might," "outlook,"
"plan," "project," "potential," "predict," "target," "possible,"
"will," "would," "could," "should," and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Any forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in, or implied by,
such forward-looking statements. For a discussion of these risks
and uncertainties, and other important factors, any of which could
cause Carisma's actual results to differ from those contained in
the forward-looking statements, see the "Risk Factors" set forth in
the Company's Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on August
10, 2023, as well as discussions of potential risks,
uncertainties, and other important factors in Carisma's other
recent filings with the Securities and Exchange Commission. Any
forward-looking statements that are made in this press release
speak as of the date of this press release. Carisma undertakes no
obligation to revise the forward-looking statements or to update
them to reflect events or circumstances occurring after the date of
this press release, whether as a result of new information, future
developments or otherwise, except as required by the federal
securities laws.
Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com
Investor Contact:
investors@carismatx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-present-at-upcoming-investor-conferences-301917350.html
SOURCE Carisma Therapeutics Inc.